Furosemide Stress Test and Biomarkers for the Prediction of AKI Severity
Furosemide Stress Test and Biomarkers for the Prediction of AKI Severity
复制标题
DOI：
10.1681/asn.2014060535
复制
发表时间：
2015-08-01
影响因子：
13.6
通讯作者：
Chawla, Lakhmir S.
中科院分区：
文献类型：
--
作者：
Koyner, Jay L.;Davison, Danielle L.;Chawla, Lakhmir S.
临床医生可以使用有限的工具来预测哪些早期阿基患者将进展到更严重的阶段。在早期阿基中，呋塞米负荷试验（FST）后的尿量，包括静脉注射呋塞米（1.0或1.5 mg/kg），可以预测3期阿基的发展。我们在先前发表的77例接受FST的早期阿基患者队列中测量了几种阿基生物标志物，并评估了FST尿量和生物标志物预测3阿基（n=25 [32.5%]）、RRT（n=11 [14.2%]）或住院死亡率（n=16 [20.7%]）发展的能力。曲线下面积（AUC）+/- SEM为0.87 +/- 0.09（P
Clinicians have access to limited tools that predict which patients with early AKI will progress to more severe stages. In early AKI, urine output after a furosemide stress test (FST), which involves intravenous administration of furosemide (1.0 or 1.5 mg/kg), can predict the development of stage 3 AKI. We measured several AKI biomarkers in our previously published cohort of 77 patients with early AKI who received an FST and evaluated the ability of FST urine output and biomarkers to predict the development of stage 3 AKI (n=25 [32.5%]) receipt of RRT (n=11 [14.2%]), or inpatient mortality (n=16 [20.7%]). With an area under the curve (AUC)+/- SEM of 0.87 +/- 0.09 (P